LOKELMATM▼ Sodium Zirconium Cyclosilicate
SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1
*In an emergency situation, standard of care should be used in line with local or national guidelines
†Clinical trials with LOKELMA have not included exposure longer than one year
The consequences of hyperkalaemia can be life threatening5,6
Hyperkalaemia is often asymptomatic and can progress rapidly.5
Severe hyperkalaemia is a medical emergency that may cause arrhythmia and sudden death.*5
Elevated K+ is a significant predictor of mortality in patients with critical illnesses or conditions like chronic kidney disease, diabetes mellitus and heart failure.7-9
*In an emergency situation, standard of care should be used in line with local or national guidelines.
Hyperkalaemia and Mortality Risk
Higher serum K+ levels and comorbidities increase the mortality risk associated
Risk of all-cause mortality by serum K+ level and comorbidities in US electronic health record data. Spline analysis adjusted for covariates, showing serum K+ as a continuous variable with all-cause mortality18
Adapted from Collins AJ, et al. Am J Nephrol. 2017;46:213-221.